Abstract:Introduction: Synthetic DNA technology is rapidly emerging as a key driver of innovation in the fields of medicine, biotechnology, and more. But it also poses significant risk, particularly in lowering barriers to the production of dangerous pathogens and toxins. At present, oversight of this technology is voluntarily coordinated among synthetic DNA providers and stakeholders, and detailed understanding of security processes, infrastructures, and insights from these providers is imperative to understand how to best mitigate the inherent risks of this technology. Objectives: In this study, we aimed to determine the trends, outliers, strengths, and gaps in current DNA provider security practices through a broad survey of the gene synthesis field. Methods: We interviewed synthetic DNA providers and stakeholders about their customer and sequence screening procedures. Respondents were divided into groups based on membership in the International Gene Synthesis Consortium, nationality, whether they were a new or established company, and whether they synthesize de novo DNA or not. We then performed meta-analysis and intergroup analysis to elucidate larger trends and points of variance. Results: In total, we interviewed 18 companies. We found that synthetic DNA providers and stakeholders tend to operate under a "zero-trust model" for screenings and utilize common governmental and private resources to navigate international import/export policies. Major variabilities were identified in the sensitivity of screening, monitoring and evaluation practices, screening pipelines, and approaches to synthetic oligonucleotide screening. In addition, we identified a significant vulnerability of lacking awareness among providers of formal law enforcement reporting procedures. Conclusion: Collectively, we observed significant heterogeneity in security practice throughout the field, reflective of the current lack of codified oversight for DNA synthesis. The results presented in this study provide insight into the specifics, strengths, and shortcomings of current DNA provider security practices, and are important considerations for the biosecurity community in ongoing deliberations of if, when, and how to approach oversight of synthetic DNA technology.

Five Things Not to Do When Discovering a Biosecurity Vulnerability

Practical Questions for Securing Nucleic Acid Synthesis

The bioterrorism threat and dual-use biotechnological research: an Israeli perspective

Screening State of Play: The Biosecurity Practices of Synthetic DNA Providers

Next Steps for Access to Safe, Secure DNA Synthesis

Toward AI-Resilient Screening of Nucleic Acid Synthesis Orders: Process, Results, and Recommendations

Biosurveillance enterprise for operational awareness, a genomic-based approach for tracking pathogen virulence

Cyberbiosecurity: DNA Injection Attack in Synthetic Biology

Safeguarding Mail-Order DNA Synthesis in the Age of Artificial Intelligence

Biosecurity Assessments for Emerging Transdisciplinary Biotechnologies: Revisiting Biodefense in an Age of Synthetic Biology

Progress and Prospects for a Nucleic Acid Screening Test Set

Cyber-biological convergence: a systematic review and future outlook

Biosecurity: Progress and Challenges

How to build a vulnerability benchmark to overcome cyber security attacks

Artificial intelligence and biological misuse: Differentiating risks of language models and biological design tools

Bioinformatics for Biodefense: Challenges and Opportunities

Safely balancing a double-edged blade: identifying and mitigating emerging biosecurity risks in precision medicine

Random adversarial threshold search enables automated DNA screening

Peptide Toxins as Biothreats and the Potential for AI Systems to Enhance Biosecurity

A teachable moment for dual-use

CRISPR Cautions: Biosecurity Implications of Gene Editing